Mainz Biomed to unveil breakthrough early most cancers detection research outcomes at DDW 2024



Mainz Biomed N.V., a molecular genetics diagnostic firm specializing within the early detection of most cancers, will current  an evaluation from  its eAArly DETECT research at Digestive Illness Week (DDW) 2024 in Washington D.C. from Might 18th to Might twenty first. DDW is acknowledged as a premier discussion board for the newest developments in gastroenterology, hepatology, endoscopy, and gastrointestinal surgical procedure.

eAArly DETECT is a US multi-site research carried out at 21 specialised gastroenterology websites that enrolled 254 scientific sufferers . The outcomes present compelling efficiency of its multimodal screening check combining Fecal Immunochemical Take a look at (FIT), DNA and mRNA biomarkers with a singular synthetic intelligence (AI) / machine studying algorithm to distinguish between colorectal most cancers (CRC), superior adenomas (AA), non-advanced adenomas and affected person samples with no findings.

The presentation will delve into the check’s means to precisely analyze a mixture of biomarkers, bettering early detection charges for each colorectal most cancers and important precancerous circumstances. By leveraging this twin method, Mainz Biomed goals to speed up the shift from most cancers detection to prevention by advancing present colorectal most cancers screening practices, reflecting its dedication to lowering most cancers mortality charges worldwide.

Presentation particulars

Session Title: Most cancers, Early Detection, Biomarkers for Analysis, Remedy and Prognosis of GI Cancers

Session Sponsor: AGA

Title:  “NOVEL STOOL-BASED NON-INVASIVE EARLY DETECTION OF COLORECTAL CANCER AND PRECANCEROUS LESIONS BY CLASSIC FIT COMBINED WITH NUCLEIC ACID-BASED BIOMARKER SIGNATURES.”

Presenter: Kammers, L

Session: Sunday Might 19, 2024, from 12:30 PM to 1:30 PM EDT

Poster #: Su1117

Key findings: First evaluation of the eAArly DETECT scientific research reported a sensitivity for colorectal most cancers of 97% with a specificity of 97% and a sensitivity for superior adenoma of 82%. Ensuing efficiency information confirms that this multimodal screening technique displays a considerable and significant enchancment for CRC and particularly AA detection, the place improved sensitivity is urgently wanted to lower CRC incidence and mortality.

Leave a Reply

Your email address will not be published. Required fields are marked *